Dr. Pascal Ferzli, MD

Dr. Ferzli practices at Donald I. Altman MD in Irvine, California.

Dr. Ferzli's NPI, 1396906921, was assigned on June 17, 2008. Dr. Ferzli graduated from Boston University School Of Medicine in 2005. Dr. Ferzli holds California license A125157.

Dr. Ferzli's primary practice is Donald I. Altman MD, at 16300 Sand Canyon Ave, Irvine, CA 92618 in Orange County. The practice phone is (949) 727-3999.

Dr. Ferzli's primary practice is Donald I. Altman MD in Irvine, California. The medical group on file is Beach Cities Dermatology Medical Center. Dmand AI also links Dr. Ferzli to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ferzli practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Ferzli's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Ferzli is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Ferzli's licenses on file in 4 states: California, New Hampshire, Massachusetts and New Jersey.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, hives, itchy rashes and psoriasis among the conditions Dr. Ferzli treats.

CMS data shows 5,640 Medicare services from Dr. Ferzli across 21 procedure codes in 2024, for 636 Medicare patients. Medicare paid $236,739 for them. Every service was in an office.

CMS counts 636 Medicare patients who saw Dr. Ferzli in 2024. The largest group is 75 to 84, with 276 patients. 75% of them have high cholesterol, and 65% have high blood pressure. Their average risk score is 0.96, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ferzli's median patient age at 63, with 47% women.

In 2024, Dr. Ferzli wrote 365 Medicare Part D claims for 175 patients. 87% of them were for generic drugs. CMS names the drug for 249 of them, across 12 drugs with 11 or more claims each, at $122,270 in total drug cost. In 2023, CMS named 304 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Ferzli for performance year 2024, reported individually. Dr. Ferzli accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,001 procedures of skin biopsy by Dr. Ferzli, more than 99% of the clinicians it reports for that procedure.

Removal of skin cancer: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 3 papers to Dr. Ferzli. The most frequent topics are Skin Neoplasms. Dr. Ferzli has published most often in Cutis.

CMS Open Payments shows 240 general payments to Dr. Ferzli from 26 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $785.

Dr. Ferzli graduated from Boston University School Of Medicine in 2005.

Dr. Ferzli is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.